Literature DB >> 8098267

Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score.

S R Tahan1, D S Neuberg, A Dieffenbach, L Yacoub.   

Abstract

BACKGROUND: Cell cycle kinetic measures have been shown to have prognostic significance in breast cancer. Methods that have been used to assess the proliferating fraction of tumors include measurements of DNA content with S-phase calculation by flow cytometric analysis, radioisotope-labeled nucleotide incorporation, and cell cycle-associated protein expression. The recent discovery of the S-phase-specific nuclear protein proliferating cell nuclear antigen (PCNA) opens the door for a novel approach to cell kinetic measurement with an immunocytochemical assay.
METHODS: A quantitative immunocytochemical assay for PCNA was performed on 82 primary invasive breast carcinomas fixed in formaldehyde solution and embedded in paraffin and 18 corresponding axillary metastases. The percentage of tumor cells with strong nuclear staining was determined by visual count. This PCNA score was correlated with histologic parameters, age, relapse intervals, and long-term survival.
RESULTS: PCNA scores were distributed normally among primary carcinomas (range, 5-54; mean, 22.5). Carcinomas had much higher scores than adjacent normal epithelium (means, 22.5 and 4.1, respectively; P < 0.00001), and axillary node metastases had slightly higher scores than corresponding primary breast tumors (means 26.4 and 22.5, respectively; P = 0.05). The PCNA score did not correlate with age, tumor size, axillary node status, intramammary lymphatic-vascular invasion, or estrogen and progesterone binding capacities. Furthermore, its variability could not be explained by grade. PCNA values increased as the mitotic rate increased. Cancers with high PCNA scores (> or = 25) were associated with shorter disease-free (P = 0.007) and overall survival times (P = 0.01) than tumors with low PCNA scores (< 25) (median follow-up, 166 months).
CONCLUSIONS: PCNA score has potential value as a prognostic indicator in breast cancer. This method of assessing the proliferating pool offers advantages over other assays in terms of relative simplicity of the method, applicability to paraffin-embedded fixed tissue, and low cost.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098267     DOI: 10.1002/1097-0142(19930601)71:11<3552::aid-cncr2820711115>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Role of transforming growth factor-[beta]1 in inhibiting endothelial cell proliferation in experimental alcoholic liver disease.

Authors:  A A Nanji; S R Tahan; M Golding; S Khwaja; A Rahemtulla; E N Lalani
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  Antiproliferative effect of peripheral benzodiazepine receptor antagonist PK11195 in rat mammary tumor cells.

Authors:  Sutapa Mukhopadhyay; Bobby Guillory; Shyamali Mukherjee; Salil K Das
Journal:  Mol Cell Biochem       Date:  2010-03-04       Impact factor: 3.396

4.  Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas.

Authors:  T Haerslev; G K Jacobsen; K Zedeler
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker.

Authors:  Linda H Malkas; Brittney Shea Herbert; Waleed Abdel-Aziz; Lacey E Dobrolecki; Yang Liu; Beamon Agarwal; Derek Hoelz; Sunil Badve; Lauren Schnaper; Randy J Arnold; Yehia Mechref; Milos V Novotny; Patrick Loehrer; Robert J Goulet; Robert J Hickey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-11       Impact factor: 11.205

6.  A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Authors:  Shanna J Smith; Long Gu; Elizabeth A Phipps; Lacey E Dobrolecki; Karla S Mabrey; Pattie Gulley; Kelsey L Dillehay; Zhongyun Dong; Gregg B Fields; Yun-Ru Chen; David Ann; Robert J Hickey; Linda H Malkas
Journal:  Mol Pharmacol       Date:  2014-12-05       Impact factor: 4.436

Review 7.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

8.  Proliferating cell nuclear antigen in breast carcinomas. An immunohistochemical study with correlation to histopathological features and prognostic factors.

Authors:  T Haerslev; G K Jacobsen
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Lead article: The prognostic significance of proliferating cell nuclear antigen (pcna) in laryngeal cancer.

Authors:  T Sapci; F Filizel; A Karavus; U G Akbulut; M Karavus
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1998-10

10.  CAPER, a novel regulator of human breast cancer progression.

Authors:  Isabelle Mercier; Donna M Gonzales; Kevin Quann; Timothy G Pestell; Alexander Molchansky; Federica Sotgia; James Hulit; Ricardo Gandara; Chenguang Wang; Richard G Pestell; Michael P Lisanti; Jean-François Jasmin
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.